Characteristics of 1738 Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China

Ma, Xiao; Gao, Yujing; Di, Lingling; Ma, Hanning; Mei, Bin; Zhang, Junjian; Wang, Amei; Feng, Ke; Yang, Le-Min; Chen, Zhongwei

doi:10.1017/dmp.2021.129

Cited by 3 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major cause of death in patients with COVID-19 is hypoxic respiratory failure due to a combination of parenchymal and vascular changes, similar to those encountered in acute respiratory distress syndrome (ARDS) due to other causes 101 . However, several studies have suggested possibly specific features in ARDS caused by COVID-19 (refs 38 , 102 ).…”

Section: Pulmonary Vascular Pathobiology In Covid-19mentioning

confidence: 99%

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

et al. 2021

View full text Add to dashboard Cite

The lungs are the primary target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with severe hypoxia being the cause of death in the most critical cases. Coronavirus disease 2019 (COVID-19) is extremely heterogeneous in terms of severity, clinical phenotype and, importantly, global distribution. Although the majority of affected patients recover from the acute infection, many continue to suffer from late sequelae affecting various organs, including the lungs. The role of the pulmonary vascular system during the acute and chronic stages of COVID-19 has not been adequately studied. A thorough understanding of the origins and dynamic behaviour of the SARS-CoV-2 virus and the potential causes of heterogeneity in COVID-19 is essential for anticipating and treating the disease, in both the acute and the chronic stages, including the development of chronic pulmonary hypertension. Both COVID-19 and chronic pulmonary hypertension have assumed global dimensions, with potential complex interactions. In this Review, we present an update on the origins and behaviour of the SARS-CoV-2 virus and discuss the potential causes of the heterogeneity of COVID-19. In addition, we summarize the pathobiology of COVID-19, with an emphasis on the role of the pulmonary vasculature, both in the acute stage and in terms of the potential for developing chronic pulmonary hypertension. We hope that the information presented in this Review will help in the development of strategies for the prevention and treatment of the continuing COVID-19 pandemic.

show abstract

Section: Pulmonary Vascular Pathobiology In Covid-19mentioning

confidence: 99%

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

et al. 2021

View full text Add to dashboard Cite

show abstract

“…One study was a survey that included patient data from two regions, Hong Kong and mainland China, separately, so we analyzed the data separately ( 71 ). Twenty-two studies were conducted in China ( 27 , 31 – 34 , 37 , 39 , 40 , 44 , 47 , 55 , 62 – 65 , 67 , 69 – 73 , 75 – 77 ), six in Saudi Arabia ( 18 , 21 – 23 , 25 , 26 ), five in India ( 10 , 41 , 46 , 60 , 61 ), three in the United States ( 35 , 42 , 45 ) and three in Turkey ( 38 , 49 , 66 ), and these were the most frequent countries included in this review. Among the population-based survey studies, thirty-one were conducted through online surveys only ( 17 , 18 , 20 , 22 , 23 , 25 , 26 , 28 – 31 , 35 , 42 , 43 , 45 , 48 – 54 , 57 – 62 , 66 , 68 , 74 ), one was an in-person interview ( 56 ), three were telephone interviews ( 10 , 21 , 38 ), and two were both in-person and online surveys ( 19 , 36 ).…”

Section: Resultsmentioning

confidence: 99%

“…Among the population-based survey studies, thirty-one were conducted through online surveys only ( 17 , 18 , 20 , 22 , 23 , 25 , 26 , 28 – 31 , 35 , 42 , 43 , 45 , 48 – 54 , 57 – 62 , 66 , 68 , 74 ), one was an in-person interview ( 56 ), three were telephone interviews ( 10 , 21 , 38 ), and two were both in-person and online surveys ( 19 , 36 ). Among the included studies, usage status of the interventions, including TCM ( n = 22) ( 27 , 32 – 34 , 37 , 39 , 40 , 44 , 47 , 55 , 63 – 65 , 67 , 69 – 73 , 75 – 77 ), functional food (supplements) or herbs ( n = 20) ( 17 – 24 , 29 , 36 , 38 , 43 , 49 – 52 , 57 – 59 ), mind-body practice or spiritual practice ( n = 9) ( 28 , 35 , 42 , 45 , 48 , 54 , 60 , 61 , 74 ), Ayurveda ( n = 2) ( 10 , 41 ), homeopathy ( n = 1) ( ...…”

Section: Resultsmentioning

confidence: 99%

“…Most of the data for surveys or patient chart reviews were collected during 2020. In approximately half of the studies, TCIM interventions were used for prophylactic purposes ( n = 28) ( 17 – 20 , 22 , 23 , 25 , 26 , 28 , 31 , 35 , 36 , 38 , 41 , 42 , 45 , 48 – 54 , 59 , 61 , 62 , 66 , 74 ), and the other half were used for therapeutic purposes ( n = 27) ( 21 , 24 , 27 , 32 – 34 , 37 , 39 , 40 , 44 , 46 , 47 , 55 , 58 , 63 – 65 , 67 , 69 – 73 , 75 – 77 ) ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of Traditional, Complementary and Integrative Medicine During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundTraditional, Complementary and Integrative Medicine (TCIM) has been reported to use for symptom management of coronavirus disease 2019 (COVID-19). The objective of this review was to identify the overall usage prevalence of TCIM interventions for COVID-19.MethodsSurveys on the general population and observational studies on the COVID-19 patient chart review were located in the search of PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases in September 2021. Observational studies, such as cross-sectional studies, surveys, cohort studies and hospital-based patient case reviews, published in any language, reporting the usage of TCIM in the patients with COVID-19 or the general population during the COVID-19 pandemic were included in this review. Data screening and extraction were performed independently by two reviewers. The reporting quality of the included studies was assessed with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. To conduct a meta-analysis of the usage prevalence of various TCIM interventions, the effect size of the proportion for each intervention was calculated with the inverse variance method. The main outcome was usage prevalence of TCIM interventions among patients with COVID-19 or the general population during the COVID-19 pandemic.ResultsA total of 62 studies were included in this review. The overall TCIM usage prevalence was estimated to be 0.64 (95% CI 0.54–0.73). The overall prevalence did not differ between the population-based survey (0.65, 95% CI 0.48–0.81) and the hospital-based patient case review (0.63, 95% CI 0.52–0.73). Statistical heterogeneity and comparatively low quality in reporting were observed, which should be cautiously considered when interpreting the results.ConclusionVarious TCIM interventions were reported to be used with comparatively high frequency. Future international collaborative research might overcome the main limitation of this study, i.e., the heterogeneity of the included data.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278452, identifier: CRD42021278452.

show abstract

VEGF Polymorphisms (VEGF-936 C/T, VEGF-634 G/C and VEGF-2578 C/A) and Cardiovascular Implications in Long COVID Patients

Cozma,

Sitar-Tăuț,

Orășan

et al. 2024

IJMS

View full text Add to dashboard Cite

The COVID-19 pandemic has raised awareness of the virus’s long-term non-pulmonary consequences. This study examined the relationship between genetic polymorphisms of VEGF and cardiac dysfunction and subclinical atherosclerosis in patients recovering from COVID-19. This study included 67 patients previously diagnosed with COVID-19. VEGF-936C/T, VEGF-634G/C, and VEGF-2578C/A statuses were determined. Conventional echocardiography and arterial parameters assessments were performed at inclusion and at six months after the first assessment. For VEGF-936C/T, dominant and over-dominant models showed a significant increase in ejection fraction at six months after COVID (p = 0.044 and 0.048) and was also a predictive independent factor for the augmentation index (β = 3.07; p = 0.024). The dominant model showed a rise in RV-RA gradient (3.702 mmHg) (p = 0.028 95% CI: 0.040–7.363), with the over-dominant model indicating a greater difference (4.254 mmHg) (p = 0.025 95% CI: 0.624–7.884). The findings for VEGF-634G/C were not statistically significant, except for a difference in TAPSE during initial evaluation, using the codominant model. For VEGF-2578C/A, a difference in ventricular filling pressure (E/E’ratio) was best described under the recessive model. Our research suggests that the VEG-936C/T genotype may impact the baseline level and subsequent changes in cardiac function and subclinical atherosclerosis. These findings offer valuable insights into the complex correlation between genetic polymorphisms and cardiovascular disfunction in long COVID patients.

show abstract

Characteristics of 1738 Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China

Cited by 3 publications

References 8 publications

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

Use of Traditional, Complementary and Integrative Medicine During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis

VEGF Polymorphisms (VEGF-936 C/T, VEGF-634 G/C and VEGF-2578 C/A) and Cardiovascular Implications in Long COVID Patients

Contact Info

Product

Resources

About